Of the remaining negative studies, four [39, 45, 55, 58] involved participants with mixed breast cancer, one [24] was restricted to participants with the HER2 + phenotype, and two [47, 54] focused on patients with luminal breast cancer. Here, ERBB2 is linked to breast carcinoma.